What's Happening?
INOVIO and Akeso have announced a clinical collaboration to evaluate a novel combination therapy for glioblastoma (GBM), the most aggressive form of brain cancer. The collaboration will test INOVIO's DNA immunotherapy candidate, INO-5412, in combination with
Akeso's bispecific antibody, cadonilimab. This study is part of the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute. The trial aims to find new treatments for GBM by using a shared control arm to test multiple therapies simultaneously. The combination therapy is expected to begin dosing in the second half of 2026. Previous trials have shown that INO-5412, when combined with a PD-1 checkpoint inhibitor, elicited strong immune responses potentially linked to improved survival rates.
Why It's Important?
This collaboration is significant as it addresses the urgent need for effective treatments for glioblastoma, a cancer with limited therapeutic options and poor prognosis. The combination of INOVIO's DNA medicine with Akeso's dual checkpoint inhibition could offer a new avenue for treatment, potentially improving patient outcomes. The trial's design allows for rapid evaluation of multiple therapies, which could accelerate the development of effective treatments. Success in this trial could lead to broader applications of the therapy in other cancers, enhancing the therapeutic landscape and offering hope to patients with few alternatives.
What's Next?
The INSIGhT trial will proceed with the combination therapy's dosing expected to start in late 2026. The trial will assess the safety and efficacy of the therapy in patients with newly diagnosed GBM. If successful, this could lead to further clinical trials and eventual regulatory approval. Stakeholders, including healthcare providers and patients, will be closely monitoring the trial's progress. The collaboration between INOVIO and Akeso may also pave the way for future partnerships in cancer treatment development.
